A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Nu 3 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors Lakewood Amedex
- 04 Apr 2017 According to a Lakewood Amedex media release, top-line data from the study is anticipated in the second quarter 2017.
- 10 Mar 2017 Study design has been changed from three cohort to five cohort. Also elderly patients are also enrolled in the trial.
- 10 Mar 2017 Planned number of patients changed from 30 to 50.